Related Experiment Video
Updated: Apr 5, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
The consideration of indolicidin modification to balance its hemocompatibility and delivery efficiency
Ching-Wei Tsai1, Wei-Wen Hu1, Chih-I Liu2
1Department of Chemical and Materials Engineering, National Central University, Taoyuan City, Taiwan.
Abstract:
Indolicidin (IL) is an antimicrobial peptide (AMP), which has been utilized as a cell penetrating peptide (CPP) for drug delivery. However, the hemolysis restricts its clinical application. Therefore, we investigated the delivery efficiency and hemocompatibility of IL and its derivatives. The transportation of fluorophore to NIH/3T3 cells could be improved either by in accompany with these peptides or in the form of peptide-conjugates. The hydrophobicity scales of these peptides were calculated according to their residues, which were compared to their effects on hemolysis as well as cell uptake efficiency. The results suggested that the cell penetrability of IL and its derivatives was related to their hydrophobicity scales based on the octanol-interface scale (ΔGoct-if), whereas their hemolysis levels depended on the hydrophobicity scales based on interface (ΔGwif). Consequently, we designed two peptides, IL-R57F89 and SAP10, to validate the correlation. These two peptides had similar ΔGwif; however, the ΔGoct-if of SAP10 was much higher than that of IL-K7F89. Both IL-R57F89 and SAP10 demonstrated extremely low hemolysis. Compared to the limit cell uptake of SAP10, IL-R57F89 greatly promoted the delivery efficiency. These results were consistent to our prediction, suggesting that hydrophobicity scales should be a useful preliminary guidance for AMP-derived CPP design.
More Related Videos
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
10:15The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
Published on: August 20, 2014
Related Concept Videos
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Bioavailability
Site-Targeted Drug Delivery Systems: Polymeric Carriers